In this work, we dissect the molecular mechanisms underlying epigenetic regulations of the Nrg1 enhancer that drive Nrg1 overexpression in breast cancer cells under hyperglycemic conditions and define therapeutic strategies for overcoming drug resistance and breast cancer recurrence in patients with diabetes. This evidence concerns the gene NRG1 and breast carcinoma.